Swedish Orphan Biovitrum AB (publ) (BIOVF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Swedish Orphan Biovitrum AB (publ) (BIOVF) with AI Score 56/100 (Hold). Swedish Orphan Biovitrum AB (publ) (Sobi) is a biopharmaceutical company focused on providing treatments for rare diseases and specialty care. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Swedish Orphan Biovitrum AB (publ) (BIOVF) Healthcare & Pipeline Overview
Swedish Orphan Biovitrum AB (publ) (Sobi) is a biopharmaceutical company specializing in haematology, immunology, and specialty care, offering treatments for rare diseases across Europe, North America, the Middle East, Asia, and Australia. With a focus on innovative therapies, Sobi addresses unmet medical needs in niche markets, maintaining a $14.70B market capitalization.
Investment Thesis
Swedish Orphan Biovitrum AB (publ) presents a focused investment opportunity within the rare disease and specialty care biopharmaceutical sector. With a market capitalization of $14.70B and a gross margin of 78.9%, Sobi demonstrates financial stability. Key value drivers include the continued growth of its haematology and immunology portfolios, particularly Alprolix, Elocta/Eloctate, and Aspaveli/Empaveli. Upcoming catalysts include potential regulatory approvals for new indications and expansion into new geographic markets. However, investors should be aware of risks such as competition from biosimilars and potential setbacks in clinical trials. The company's ROE of 1.2% and profit margin of 1.7% suggest areas for improvement in operational efficiency.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $14.70B reflects Sobi's significant presence in the biopharmaceutical industry.
- Gross Margin of 78.9% indicates strong pricing power and efficient cost management.
- Debt-to-Equity Ratio of 30.47 suggests a balanced capital structure.
- Profit Margin of 1.7% indicates potential for improvement in operational efficiency.
- Beta of 0.23 suggests lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Specialized product portfolio in rare diseases.
- Global presence and distribution network.
- Strong partnerships with other pharmaceutical companies.
- Focus on innovative therapies and unmet medical needs.
Weaknesses
- Limited product diversification.
- Dependence on key products for revenue.
- Relatively small size compared to major pharmaceutical companies.
- Lower profit margin compared to industry peers.
Catalysts
- Upcoming: Potential regulatory approvals for new indications of existing products.
- Ongoing: Expansion of Aspaveli/Empaveli into new markets.
- Ongoing: Continued growth in the haematology portfolio.
- Upcoming: Results from ongoing clinical trials for novel therapies.
- Ongoing: Strategic collaborations and acquisitions to expand product pipeline.
Risks
- Potential: Competition from biosimilars and generic drugs.
- Potential: Regulatory challenges and pricing pressures.
- Potential: Clinical trial failures and product recalls.
- Ongoing: Dependence on key products for revenue.
- Ongoing: Economic downturns and healthcare reforms.
Growth Opportunities
- Expansion of Haematology Portfolio: Sobi can further expand its haematology portfolio by developing and commercializing new treatments for haemophilia and other blood disorders. The global market for haemophilia treatment is projected to reach $14.5 billion by 2028. Sobi's existing products, Alprolix and Elocta/Eloctate, provide a strong foundation for continued growth in this area. Success hinges on regulatory approvals and market penetration in key geographies.
- Growth in Immunology Segment: Sobi's immunology segment, driven by Aspaveli/Empaveli for paroxysmal nocturnal haemoglobinuria (PNH), presents a significant growth opportunity. The PNH market is expected to grow as awareness and diagnosis improve. Sobi can capitalize on this trend by expanding the availability of Aspaveli/Empaveli and developing new therapies for other immunological disorders. The timeline for realizing this growth depends on clinical trial outcomes and regulatory approvals.
- Geographic Expansion: Sobi has the opportunity to expand its geographic footprint, particularly in emerging markets. These markets offer significant growth potential due to increasing healthcare spending and unmet medical needs. Sobi can leverage its existing product portfolio and partnerships to enter new markets and establish a presence. This expansion strategy requires careful market analysis and strategic partnerships to navigate local regulations and distribution channels.
- Strategic Collaborations and Acquisitions: Sobi can pursue strategic collaborations and acquisitions to expand its product pipeline and therapeutic expertise. Collaborating with other biopharmaceutical companies and research institutions can accelerate the development of new therapies and broaden Sobi's portfolio. Acquisitions can provide access to new technologies, products, and markets. These strategic moves can enhance Sobi's long-term growth prospects and competitive position.
- Development of Novel Therapies: Investing in the research and development of novel therapies for rare diseases and specialty care is crucial for Sobi's long-term growth. By focusing on innovative treatments that address unmet medical needs, Sobi can differentiate itself from competitors and capture market share. This requires a strong R&D pipeline, strategic partnerships, and a commitment to scientific excellence. The timeline for realizing this growth depends on the success of clinical trials and regulatory approvals.
Opportunities
- Expansion into new therapeutic areas and geographic markets.
- Strategic collaborations and acquisitions.
- Development of novel therapies for rare diseases.
- Increasing awareness and diagnosis of rare diseases.
Threats
- Competition from biosimilars and generic drugs.
- Regulatory challenges and pricing pressures.
- Clinical trial failures and product recalls.
- Economic downturns and healthcare reforms.
Competitive Advantages
- Specialized product portfolio focused on rare diseases.
- Strong relationships with healthcare providers and patient advocacy groups.
- Intellectual property protection for its key products.
- Global distribution network and commercial infrastructure.
About BIOVF
Swedish Orphan Biovitrum AB (publ), also known as Sobi, was founded in 1939 and is headquartered in Stockholm, Sweden. The company has evolved into a global biopharmaceutical leader focused on rare diseases and specialty care. Sobi operates through three primary segments: Haematology, Immunology, and Specialty Care. Its product portfolio includes Alprolix and Elocta/Eloctate for haemophilia, Aspaveli/Empaveli for paroxysmal nocturnal haemoglobinuria, Doptelet for thrombocytopenia, Gamifant for hemophagocytic lymphohistiocytosis, Kineret for various inflammatory conditions, Orfadin for hereditary tyrosinemia type 1 and alkaptonuria, Synagis for respiratory syncytial virus prevention in infants, VONJO for myelofibrosis, and Zynlonta for lymphoma. Sobi also provides other medicines like Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra. The company collaborates with partners like Sanofi, Apellis Pharmaceuticals, ADC Therapeutics, and Cartesian Therapeutics to develop and commercialize innovative therapies. Sobi's global presence extends across Europe, North America, the Middle East, Asia, and Australia, reflecting its commitment to addressing unmet medical needs worldwide.
What They Do
- Develops and commercializes treatments for rare diseases.
- Offers therapies in haematology, immunology, and specialty care.
- Provides Alprolix and Elocta/Eloctate for haemophilia A and B.
- Offers Aspaveli/Empaveli for paroxysmal nocturnal haemoglobinuria.
- Provides Doptelet for the treatment of immune thrombocytopenia.
- Offers Gamifant for treating hemophagocytic lymphohistiocytosis.
- Develops drug substances for ReFacto AF/Xyntha for Pfizer.
Business Model
- Develops and manufactures specialized pharmaceuticals.
- Commercializes and distributes its products globally.
- Collaborates with other companies for research and development.
- Focuses on niche markets with high unmet medical needs.
Industry Context
Swedish Orphan Biovitrum AB (publ) operates within the specialty and generic drug manufacturing industry, characterized by intense competition, stringent regulatory requirements, and high R&D costs. The market for rare disease treatments is growing, driven by increased awareness, improved diagnostics, and regulatory incentives. Key competitors include companies like Sanofi and Apellis Pharmaceuticals. Sobi's focus on haematology, immunology, and specialty care positions it to capitalize on the increasing demand for innovative therapies in these areas. The global biopharmaceutical market is expected to continue its growth trajectory, driven by aging populations and advancements in medical technology.
Key Customers
- Patients with rare diseases and specialty care needs.
- Hospitals and clinics that treat these patients.
- Healthcare providers who prescribe Sobi's medications.
- Distributors and pharmacies that supply Sobi's products.
Financials
Chart & Info
Swedish Orphan Biovitrum AB (publ) (BIOVF) stock price: Price data unavailable
Latest News
No recent news available for BIOVF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIOVF.
Price Targets
Wall Street price target analysis for BIOVF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BIOVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
BIOVF OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) securities. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is distinct from exchanges like NYSE or NASDAQ, which have stricter listing standards, including minimum share price, market capitalization, and financial reporting requirements. Investing in OTC Other stocks carries higher risks due to the lack of transparency and regulatory oversight compared to exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Higher bid-ask spreads can increase transaction costs.
- Potential for fraud or manipulation due to less regulatory oversight.
- Delisting risk if the company fails to meet minimum requirements.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Monitor trading volume and price volatility.
- Understand the risks associated with OTC investing.
- Consult with a financial advisor before investing.
- Established history of operations since 1939.
- Global presence and distribution network.
- Partnerships with reputable pharmaceutical companies.
- Focus on developing and commercializing innovative therapies.
- Presence in the haematology, immunology, and specialty care sectors.
BIOVF Healthcare Stock FAQ
What does Swedish Orphan Biovitrum AB (publ) do?
Swedish Orphan Biovitrum AB (publ) (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for rare diseases and specialty care. Sobi focuses on haematology, immunology, and specialty care, offering treatments for conditions like haemophilia, paroxysmal nocturnal haemoglobinuria, and immune thrombocytopenia. The company's business model involves developing, manufacturing, and commercializing specialized pharmaceuticals, often targeting niche markets with high unmet medical needs. Sobi collaborates with other companies for research and development, expanding its product pipeline and therapeutic expertise. With a global presence, Sobi distributes its products to patients, hospitals, and healthcare providers worldwide.
What do analysts say about BIOVF stock?
Analyst coverage of Swedish Orphan Biovitrum AB (publ) (BIOVF) is pending, but key valuation metrics include a market capitalization of $14.70B and a gross margin of 78.9%. Growth considerations revolve around the company's ability to expand its product portfolio, penetrate new markets, and navigate regulatory challenges. Investors should monitor the company's financial performance, clinical trial results, and strategic initiatives to assess its long-term growth potential. The company's ROE of 1.2% and profit margin of 1.7% suggest areas for improvement in operational efficiency.
What are the main risks for BIOVF?
Swedish Orphan Biovitrum AB (publ) (BIOVF) faces several risks inherent to the biopharmaceutical industry. Competition from biosimilars and generic drugs poses a threat to its revenue stream. Regulatory challenges and pricing pressures can impact the profitability of its products. Clinical trial failures and product recalls can disrupt its operations and damage its reputation. The company's dependence on key products for revenue concentration also presents a risk. Additionally, economic downturns and healthcare reforms can affect the demand for its products and services.
What are the key factors to evaluate for BIOVF?
Swedish Orphan Biovitrum AB (publ) (BIOVF) currently holds an AI score of 56/100, indicating moderate score. Key strength: Specialized product portfolio in rare diseases.. Primary risk to monitor: Potential: Competition from biosimilars and generic drugs.. This is not financial advice.
How frequently does BIOVF data refresh on this page?
BIOVF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BIOVF's recent stock price performance?
Recent price movement in Swedish Orphan Biovitrum AB (publ) (BIOVF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product portfolio in rare diseases.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BIOVF overvalued or undervalued right now?
Determining whether Swedish Orphan Biovitrum AB (publ) (BIOVF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BIOVF?
Before investing in Swedish Orphan Biovitrum AB (publ) (BIOVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide additional insights.
- OTC market data may be less reliable than exchange-listed data.